Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 117 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis April 10, 2025 Spring Budget 2023: What does it mean for the mission to... March 15, 2023 Should CAR T Cells Be Used Earlier in People with Non-Hodgkin... January 13, 2022 FDA Approves Durvalumab for Muscle Invasive Bladder Cancer May 2, 2025 Load more HOT NEWS Accepting Help During Cancer Is Hard, But It Can Benefit You... Nivolumab/Ipilimumab Combination Should Precede Dual BRAF/MEK Inhibition in Patients with BRAF-Mutated... First Study Examining Mental Illness and Self-Harm Events Across 26 Cancer... Outcomes From Second-Line Chemotherapy in Patients with Cholangiocarcinoma and FGFR2 Fusions
